🎉 M&A multiples are live!
Check it out!

SpringWorks Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for SpringWorks Therapeutics and similar public comparables like Julphar, Benevolent AI, and Galapagos.

SpringWorks Therapeutics Overview

About SpringWorks Therapeutics

SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing, and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing prevalent, genetically defined cancers. OGSIVEO, the first commercial product, is a novel, oral, selective gamma-secretase inhibitor. GOMEKLI, the second commercial product, is an oral, small molecule mitogen-activated protein kinase, or MEK, inhibitor.


Founded

2017

HQ

United States of America
Employees

368

Financials

LTM Revenue $236M

LTM EBITDA -$251M

EV

$2.5B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

SpringWorks Therapeutics Financials

SpringWorks Therapeutics has a last 12-month revenue of $236M and a last 12-month EBITDA of -$251M.

In the most recent fiscal year, SpringWorks Therapeutics achieved revenue of $192M and an EBITDA of -$275M.

SpringWorks Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See SpringWorks Therapeutics valuation multiples based on analyst estimates

SpringWorks Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $5.4M $192M XXX XXX XXX
Gross Profit n/a $5.0M XXX XXX XXX
Gross Margin NaN% 3% XXX XXX XXX
EBITDA -$341M -$275M XXX XXX XXX
EBITDA Margin -6267% -143% XXX XXX XXX
Net Profit -$277M -$325M XXX XXX XXX
Net Margin -5093% -170% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

SpringWorks Therapeutics Stock Performance

As of April 15, 2025, SpringWorks Therapeutics's stock price is $37.

SpringWorks Therapeutics has current market cap of $2.8B, and EV of $2.5B.

See SpringWorks Therapeutics trading valuation data

SpringWorks Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$2.5B $2.8B XXX XXX XXX XXX $-3.13

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

SpringWorks Therapeutics Valuation Multiples

As of April 15, 2025, SpringWorks Therapeutics has market cap of $2.8B and EV of $2.5B.

SpringWorks Therapeutics's trades at 10.6x LTM EV/Revenue multiple, and -10.0x LTM EBITDA.

Analysts estimate SpringWorks Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for SpringWorks Therapeutics and 10K+ public comps

SpringWorks Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $2.5B XXX XXX XXX
EV/Revenue 13.1x XXX XXX XXX
EV/EBITDA -9.1x XXX XXX XXX
P/E -10.9x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -12.8x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get SpringWorks Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

SpringWorks Therapeutics Valuation Multiples

SpringWorks Therapeutics's NTM/LTM revenue growth is 80%

SpringWorks Therapeutics's revenue per employee for the last fiscal year averaged $0.5M, while opex per employee averaged $1.2M for the same period.

Over next 12 months, SpringWorks Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate SpringWorks Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for SpringWorks Therapeutics and other 10K+ public comps

SpringWorks Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 3417% XXX XXX XXX XXX
EBITDA Margin -143% XXX XXX XXX XXX
EBITDA Growth -20% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -63% XXX XXX XXX XXX
Revenue per Employee $0.5M XXX XXX XXX XXX
Opex per Employee $1.2M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 134% XXX XXX XXX XXX
R&D Expenses to Revenue 105% XXX XXX XXX XXX
Opex to Revenue 239% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

SpringWorks Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

SpringWorks Therapeutics M&A and Investment Activity

SpringWorks Therapeutics acquired  XXX companies to date.

Last acquisition by SpringWorks Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . SpringWorks Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by SpringWorks Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About SpringWorks Therapeutics

When was SpringWorks Therapeutics founded? SpringWorks Therapeutics was founded in 2017.
Where is SpringWorks Therapeutics headquartered? SpringWorks Therapeutics is headquartered in United States of America.
How many employees does SpringWorks Therapeutics have? As of today, SpringWorks Therapeutics has 368 employees.
Who is the CEO of SpringWorks Therapeutics? SpringWorks Therapeutics's CEO is Mr. Saqib Islam, J.D..
Is SpringWorks Therapeutics publicy listed? Yes, SpringWorks Therapeutics is a public company listed on NAS.
What is the stock symbol of SpringWorks Therapeutics? SpringWorks Therapeutics trades under SWTX ticker.
When did SpringWorks Therapeutics go public? SpringWorks Therapeutics went public in 2019.
Who are competitors of SpringWorks Therapeutics? Similar companies to SpringWorks Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of SpringWorks Therapeutics? SpringWorks Therapeutics's current market cap is $2.8B
What is the current revenue of SpringWorks Therapeutics? SpringWorks Therapeutics's last 12-month revenue is $236M.
What is the current EBITDA of SpringWorks Therapeutics? SpringWorks Therapeutics's last 12-month EBITDA is -$251M.
What is the current EV/Revenue multiple of SpringWorks Therapeutics? Current revenue multiple of SpringWorks Therapeutics is 10.6x.
What is the current EV/EBITDA multiple of SpringWorks Therapeutics? Current EBITDA multiple of SpringWorks Therapeutics is -10.0x.
What is the current revenue growth of SpringWorks Therapeutics? SpringWorks Therapeutics revenue growth between 2023 and 2024 was 3417%.
Is SpringWorks Therapeutics profitable? Yes, SpringWorks Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.